All In Biotech

Drug Trial Radar · NCT05801237

PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

A Phase Ib/II Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

Last checked: Nov 19, 2026Latest source record: Dec 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Sep 21, 2023

Primary completion

Sep 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Apr 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor.

Conditions

  • Locally Advanced/Metastatic Solid Tumors

Interventions

  • PE0116&PE0105Drug

    This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Drug Limited Toxicities (DLTs)Time frame: From Time of First dose through DLT observation period, 28 days
  2. Incidence of Treatment-emergent adverse event (TEAEs) and serious adverse events (SAEs).Time frame: From the start of treatment until up to 90 days after the last dose of study drug
  3. Number of patients with changes in laboratory parameters from baselineTime frame: From the start of treatment until up to 30(±7) days after the last dose of study drug

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.